The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex

Neuropharmacology

Volumn 38, Issue 8, 1999, Pages 1175-1184

  Hertel, Peter ^a   Nomikos, George G ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

2 Adrenoceptors; 5 HT(1B) receptors; 5 HT(1D) receptors; Antipsychotic drugs; Frontal cortex; Microdialysis; Serotonin

Indexed keywords

3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; CP 135807; IDAZOXAN; ISAMOLTANE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEUROLEPTIC AGENT; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FRONTAL CORTEX; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SEROTONIN RELEASE;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORECEPTORS; FRONTAL LOBE; INDOLES; MALE; PYRIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, SEROTONIN; RISPERIDONE; SEROTONIN; SEROTONIN AGONISTS;

EID: 0032971669     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00045-3     Document Type: Article

References (79)

1. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in pathophysiology and treatment of schizophrenia. J. Neuropsych. Clin. Neurosci. 9:1997;1-17.
2. Andreasen, N.C., Rezai, K., Alliger, R., Swayze, V.W., 2d, Flaum, M., Kirchner, P., Cohen, G., O'Leary, D.S., 1992. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiat. 49, 943-958.
3. Arborelius L., Nomikos G.G., Hacksell U., Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 148:1993;465-466.
4. Baraban J.M., Aghajanian G.K. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonist. Neuropharmacology. 19:1980;355-363.
5. Berman K.F., Weinberger D.R. Prefrontal dopamine and defect symptoms in schizophrenia. Greden J.F., Tandon R. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. 1990;81-95 American Psychiatry Press, Washington DC and London.
6. Brazell M.P., Marsden C.A., Nisbet A.P., Routledge C. The 5-HT1 receptor agonist RU-24969 decreases 5-hydroxytryptamine (5-HT) release and metabolism in the rat frontal cortex in vitro and in vivo. Br. J. Pharmacol. 86:1985;209-216.
7. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 14:1995;187-202.
8. 1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 33:1994;367-386.
9. 1B binding sites in rat brain. Naunyn-Schiedeberg's Arch. Pharmacol. 347:1993;569-582.
10. Carboni E., Di Chiara G. Serotonin release estimated by transcortical dialysis in freely moving animals. Neuroscience. 32:1989;637-645.
11. Cheng C.H., Costall B., Ge J., Naylor R.J. The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats. Br. J. Pharmacol. 110:1993;1079-1084.
12. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
13. 1D autoreceptors. Br. J. Pharmacol. 114:1995;1107-1109.
14. 1D autoreceptors. Neuropharmacology. 35:1996;1627-1634.
15. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S., Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 378:1995;180-182.
16. 2-adrenoceptors. Br. J. Pharmacol. 78:1983;489-505.
17. 1B binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 332:1986;1-7.
18. Gallhofer B., Bauer U., Lis S., Krieger S., Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur. Neuropsychopharmacol. 6 Suppl. 2:1996;S13-20.
19. Garratt J.C., Crespi F., Mason R., Marsden C.A. Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur. J. Pharmacol. 193:1991;87-93.
20. 1A autoreceptors and noradrenergic mechanisms. Psychopharmacology. 130:1997;261-268.
21. Gobert A., Rivet J.M., Audinot V., NewmanTancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience. 84:1998;413-429.
22. 1B receptors with WAY 100,635 and GR 127,935. J. Neurochem. 68:1997;1159-1163.
23. Goff D.C., Midha K.K., Sarid-Segal O., Hubbard J.W., Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 117:1995;417-423.
24. Goldman M.B., Janecek H.M. Adjunctive fluoxetine improves global function in chronic schizophrenia. J. Neuropsych. Clin. Neurosci. 2:1990;429-431.
25. Göthert M., Huth H., Schlicker E. Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 317:1981;199-203.
26. Gresch P.J., Sved A.F., Zigmond M.J., Finlay J.M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem. 65:1995;111-116.
27. 1D receptor in rat and human brain. J. Neurochem. 50:1988;1624-1631.
28. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. 124:1996;74-86.
29. 2 adrenoceptor antagonism. Neuropsychopharmacology. 17:1997;44-55.
30. Hertel P., Nomikos G.G., Svensson T.H. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br. J. Pharmacol. 122:1997;1639-1646.
31. Hervás I., Bel N., Fernández A.G., Palacios J.M., Artigas F. In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei. Naunyn-Schmiedeberg's. Arch. Pharmacol. 358:1998;315-322.
32. 1B receptor agonist CP-93,129 suppresses rat hippocampal 5-HT release in vivo: comparison with RU 24969. Eur. J. Pharmacol. 209:1991;249-252.
33. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46:1994;157-203.
34. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351:1998;163-171.
35. Ingvar D.H. Evidence for frontal/prefrontal cortical dysfunction in chronic schizophrenia: the phenomenon of hypofrontality reconsidered. Helmchen H., Henn F.A. Biological Perspectives of Schizophrenia. 1987;201-211 Wiley, New York.
36. Ingvar D.H., Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr. Scand. 50:1974;425-462.
37. Iyer R.N., Bradberry C.W. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J. Pharmacol. Exp. Ther. 277:1996;40-47.
38. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiol. Rev. 72:1992;165-229.
39. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11:1997;123-131.
40. Kotrla K.J., Weinberger D.R. Brain imaging in schizophrenia. Ann. Rev. Medicine. 46:1995;113-122.
41. 1A receptors. Eur. J. Pharmacol. 260:1994;79-83.
42. 1D in the rabbit and guinea-pig brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 343:1991;353-364.
43. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br. J. Psychiat. 168:1996;571-579.
44. 1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole. J. Med. Chem. 33:1990;2087-2093.
45. Marshall D.L., Redfern P.H., Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem. 68:1997;1511-1519.
46. Matsumoto M., Yoshioka M., Togashi H., Mori K., Ueno K., Saito H. Effects of idazoxan on dopamine release in the prefrontal cortex of freely moving rats. Eur. J. Pharmacol. 343:1998;165-170.
47. 2-adrenoceptors located on serotonergic nerve terminals. Naunyn-Schmiedeberg's Arch. Pharmacol. 320:1982;272-274.
48. McQuade R., Sharp T. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem. 69:1997;791-796.
49. 1 receptor agonist, RU 24969, inhibits the efflux of 5-hydroxytryptamine from rat frontal cortex slices by stimulation of the 5-HT autoreceptor. J. Pharm. Pharmacol. 37:1985;434-437.
50. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney.
51. 1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration. J. Pharmacol. Exp. Ther. 276:1996;697-707.
52. 1B knock-out mice. Neuroreport. 7:1995;353-359.
53. 1D receptors regulate 5-HT release in the rat raphe nuclei. In vivo voltammetry and in vitro superfusion studies. Neuropsychopharmacology. 13:1995;249-260.
54. 1D receptors in the rat brain. Synapse. 22:1996;54-62.
55. 1D agonist CP-135,807. Louilot A., Durkin T., Spampinato U., Cador M. Monitoring Molecules in Neuroscience; Proceedings of the 6th International Conference on in vivo Methods. 1994;199-200 Seignosse, France.
56. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
57. Sharma R.P., Shapiro L.E., Kamath S.K., Soll E.A., Watanabe M.D., Davis J.M. Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology. 35:1997;5-10.
58. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br. J. Pharmacol. 121:1997;941-946.
59. Silver H., Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol. Psychiat. 31:1992;698-704.
60. Silver H., Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychopharmacol. 18:1998;208-211.
61. 1D receptor antagonist. Behav. Brain Res. 73:1996;157-161.
62. Soper, H.V., Elliott, R.O., Jr., Rejzer, A.A., Marshall, B.D., Jr., 1990. Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenic patients. J. Clin. Psychopharmacol. 10, 168-175.
63. Spina E., De Domenico P., Ruello C., Longobardo N., Gitto C., Ancione M., Di Rosa A.E., Caputi A.P. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int. Clin. Psychopharmacol. 9:1994;281-285.
64. Svensson T.H., Bunney B.S., Aghajanian G.K. Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine. Brain Res. 92:1975;291-306.
65. 1-adrenoceptor antagonism. J. Clin. Psychopharmacol. 15:1995;11-18.
66. 2 antagonism. Vanhoutte P.M., Saxena P.R., Paoletti R., Brunello N., Jackson A.S. Serotonin. 1993;263-270 Kluwer Academic Public and Fondazione Lorenzini, Dordrecht and Milan.
67. Svensson T.H., Tung C.-S. Local cooling of prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol. Scand. 136:1989;135-136.
68. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology. 115:1994;285-288.
69. Tao R., Hjorth S. 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:1992;137-143.
70. Toth E., Vizi E.S., Lajtha A. Effects of nicotine on levels of extracellular amino acids in regions of the rat brain in vivo. Neuropharmacology. 32:1993;827-832.
71. 2A in the rabbit. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;35-45.
72. 2-autoreceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 349:1994;25-33.
73. 1B receptors: in vivo microdialysis studies. J. Neurochem. 69:1997;2019-2025.
74. Vandermaelen C.P., Aghajanian G.K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellulary in rat brain slices. Brain Res. 289:1983;109-119.
75. Volonté M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
76. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiat. 45:1988;609-615.
77. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiat. 43:1986;114-124.
78. 1D receptor subfamily. J. Neurochem. 68:1997;410-418.
79. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem. 71:1998;274-280.